Free Trial

Biohaven (BHVN) Stock Price, News & Analysis

Biohaven logo
$13.89 -1.14 (-7.58%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$14.14 +0.25 (+1.80%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Biohaven Stock (NYSE:BHVN)

Key Stats

Today's Range
$13.81
$14.77
50-Day Range
$13.81
$22.59
52-Week Range
$13.75
$55.70
Volume
1.70 million shs
Average Volume
1.31 million shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.46
Consensus Rating
Buy

Company Overview

Biohaven Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

BHVN MarketRank™: 

Biohaven scored higher than 60% of companies evaluated by MarketBeat, and ranked 444th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biohaven has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Biohaven has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Biohaven's stock forecast and price target.
  • Earnings Growth

    Earnings for Biohaven are expected to grow in the coming year, from ($8.90) to ($6.28) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biohaven is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biohaven is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biohaven has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Biohaven's valuation and earnings.
  • Percentage of Shares Shorted

    14.27% of the float of Biohaven has been sold short.
  • Short Interest Ratio / Days to Cover

    Biohaven has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Biohaven has recently increased by 12.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Biohaven does not currently pay a dividend.

  • Dividend Growth

    Biohaven does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.27% of the float of Biohaven has been sold short.
  • Short Interest Ratio / Days to Cover

    Biohaven has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Biohaven has recently increased by 12.50%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Biohaven has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Biohaven this week, compared to 8 articles on an average week.
  • Search Interest

    Only 13 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biohaven insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Biohaven's insider trading history.
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

BHVN Stock News Headlines

Biohaven (NYSE:BHVN) Trading Down 4.5% - Time to Sell?
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
Biohaven-aandeel raakt 52-weeks dieptepunt bij $ 14,32
Biohaven Enters Oversold Territory (BHVN)
See More Headlines

BHVN Stock Analysis - Frequently Asked Questions

Biohaven's stock was trading at $37.35 at the beginning of the year. Since then, BHVN stock has decreased by 62.8% and is now trading at $13.89.

Biohaven Ltd. (NYSE:BHVN) released its quarterly earnings data on Monday, May, 12th. The company reported ($2.17) EPS for the quarter, missing the consensus estimate of ($1.67) by $0.50.

Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Top institutional investors of Biohaven include Weybosset Research & Management LLC (0.02%). Insiders that own company stock include John W Childs, Vlad Coric, Gregory Bailey, Matthew Buten and Irina Antonijevic.
View institutional ownership trends
.

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
5/12/2025
Today
7/13/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:BHVN
Previous Symbol
NASDAQ:BHVN
CIK
1935979
Fax
N/A
Employees
239
Year Founded
N/A

Price Target and Rating

High Price Target
$76.00
Low Price Target
$21.00
Potential Upside/Downside
+320.9%
Consensus Rating
Buy
Rating Score (0-4)
3.07
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($9.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$846.42 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-257.07%
Return on Assets
-164.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.33
Quick Ratio
2.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.19 per share
Price / Book
3.32

Miscellaneous

Outstanding Shares
102,113,000
Free Float
85,775,000
Market Cap
$1.42 billion
Optionable
Optionable
Beta
0.91

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NYSE:BHVN) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners